• Home
  • About
    • Psychedelic For Healthy People
    • Psilocybin (Magic Mushrooms)
    • Ayahuasca (Chacruna – Kaapi – Yajé)
    • MDMA (MDA – Sassafras)
    • Peyote Mescaline (Huachuma)
    • Kambo – Amazonian Frog
    • 5-MeO-DMT (Toad Medicine)
    • Rapé And Sacred Tobacco
    • Iboga (Ibogaine)
    • LSD (Lysergic Acid Diethylamide)
    • Cannabis (Marijuana)
    • Ketamine
    • Psychedelic Integration
    • Psychedelics Advocates
    • Frequently Asked Questions
    • Mental Health Symptoms
    • Substances Test Kits
    • Manifesto
  • Treatments
    • Latest Psychedelic Research
    • Addiction
    • Alcoholism
    • Anxiety
    • Bipolar Disorder
    • Cancer
    • Cluster Headaches
    • Depression
    • End Of Life
    • OCD
    • Neuropathy
    • Pain
    • Parkinson’s Disease
    • PTSD
    • Smoking
    • Help Treat Mental Illness
  • Microdosing
    • What is Microdosing?
    • Microdosing Magic Mushrooms
    • Microdosing LSD
    • Microdosing MDMA
    • Microdosing Ayahuasca
    • Microdosing Mescaline
    • Microdosing Cannabis
    • Microdosing Ibogaine
  • Resources
    • Past Events
    • ALL Locations
    • DMT Psychoactive Plants
    • Medical Trials And Research
    • Psychedelic Research
    • EntheoPodcasts
    • In The News
    • Books On Psychedelics
    • Related Videos
    • EntheoResources
    • Terence McKenna
    • What Is Psychedelic Art?
    • Useful Links
    • Movies & Documentaries
    • Michael Pollan
Contact
  • Follow
  • Follow
  • Follow
  • Follow

Short-acting psychedelic offers promising new treatment pathway for depression and anxiety

by EmpathiCSubstanceS | Mar 19, 2019 | Depression

A new survey into the anti-depressant qualities of a short-acting psychedelic has reported extraordinarily positive improvements in well-being. The research, led by a team from Johns Hopkins University, suggests the brief duration of action seen in the drug 5-MeO-DMT...

Ketamine-inspired nasal spray for depression on cusp of landmark FDA approval

by EmpathiCSubstanceS | Feb 13, 2019 | Depression

A new nasal spray for depression, utilizing a novel drug called esketamine, has passed the last step on its way to final FDA approval. An advisory panel to the Food and Drug Administration (FDA) voted in favor of the new drug’s risk/benefit profile meaning the...

F.D.A. Panel Recommends New Depression Treatment

by EmpathiCSubstanceS | Feb 13, 2019 | Depression

The active ingredients of ketamine, a popular club drug, show promise in battling deep despair. In a move that may clear the way for the first new treatment in years for depression, an expert panel recommended on Tuesday that federal regulators approve a nasal spray...

The Future of Psychedelics, As Explained by Michael Pollan

by EmpathiCSubstanceS | Feb 8, 2019 | Kambo

Trying to figure out what to put in our bodies to make them healthier is a full-fledged American pastime, which is why writer and journalist Michael Pollan has emerged as a beloved nutritional explorer. Pollan, the author of In Defense of Food and The Omnivore’s...

Brazil Is Giving Ayahuasca To Prison Inmates On Their Path To Redemption

by EmpathiCSubstanceS | Feb 8, 2019 | Anxiety

In a quest to ease pressures on the Brazilian prison system, mental health workers have opted to give prison inmates the psychedelic brew ayahuasca, in the hopes of helping them to work through their deeply-rooted emotional traumas. It is no secret that the current...
« Older Entries
Next Entries »

IMPORTANT NOTICE:

This community is being designed as a secure space. It is not a place to seek, encourage, or participate in the procurement of controlled substances. Do not bring, buy, sell, transfer, or arrive on any illegal substances, or swap information on how to buy them. Attendees and/or members of this community who violate these basic house rules will be removed from the community and will not be allowed to attend future events.

Psychedelic Research

Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin

Aug 17, 2022

Robust activations to the memories were seen in limbic and striatal regions in the early phase and the medial prefrontal cortex in the late phase in both conditions (P<0.001, whole brain cluster correction), but there were additional visual and other sensory...

Acute Pharmacological Effects of 2C-B in Humans: An Observational Study

Aug 17, 2022

Acute administration of 2C-B increased blood pressure and heart rate. Scores of scales related to euphoria increased (high, liking, and stimulated), and changes in perceptions (distances, colors, shapes, and lights) and different body feelings/surrounding were...

Neuroticism is associated with challenging experiences with psilocybin mushrooms

Aug 17, 2022

CEQ scores were negatively associated with emotional stability scores (the inverse of neuroticism) in Study 1 and positively associated with neuroticism scores in Study 2. Neuroticism may contribute to the strength of challenging experiences with psychedelics in...

Psychedelic Medicine

What are the countries where it’s easier to come by psychedelics?

Jul 1, 2022

The USA! Drugs of all descriptions are widely available in every major city. They’re also cheap and potent. Portugal Czech Republic Peru and Uruguay The Netherlands is known as a pot smoker’s paradise.

EGO

Jun 23, 2022

Entheogenic Liberation By Rick D. Unraveling the Enigma of Nonduality with 5-MEO-DMT Energetic Therapy This book is full of tons of facts, details, and specific information and answers all the many questions one would have upon embarking on this journey.  This outline...

Can Psilocybin Mushrooms Help Treat Eating Disorders?

Jun 11, 2022

Psilocybin or ‘Magic’ Mushrooms are catching the eye of medical enthusiasts with a niche specialty in eating disorders. In the society we’ve grown up through and into, what we have never seems to be enough. Beauty is always on the horizon, but the horizon is never...

How do we overcome PTSD with MDMA and psilocybin treatments?

Nov 9, 2021

The news last week that the compound 3,4-methylenedioxymethamphetamine (MDMA), popularly called ecstasy, alleviated post-traumatic stress disorder (PTSD) in a phase 3 trial was a milestone in efforts to turn psychedelic drugs into mainstream treatments. It also...

What has held you back from experimenting new psychedelic treatments?

Nov 9, 2021

Leonie, 44, knew where her depression came from – but that didn’t make it any easier to live with. Growing up in South Africa, where both her parents were violently attacked, left her with what she calls “a constant, low hum of insecurity and threat, almost like...

© 2025| All Rights Reserved, EntheoMedicine Community
  • Follow
  • Follow
  • Follow
  • Follow